Actively Recruiting
Copenhagen Heart Failure With Preserved Ejection Fraction
Led by Tor Biering-Sørensen · Updated on 2025-03-05
5000
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes mellitus and hypertension. In 2020, \> 70% of patients with heart failure had preserved ejection fraction. The incidence and prevalence of HFpEF has been growing by 10% every 10 years relative to HF with reduced ejection fraction (HFrEF). In 2017, the prevalence of HFpEF varied from 1% to 14% based on available data from Europe and USA. HFpEF is associated with high morbidity and mortality, and patients with HFpEF have similarly high hospitalization rates as patients with HFrEF. Hence, HFpEF poses a substantial global health challenge. Despite its prevalence, HFpEF remains undiagnosed and underrecognized, necessitating a comprehensive approach to both identification and management. Ensuring successful treatment necessitates early identification of HFpEF. Consequently, a targeted screening strategy has been devised for the identification of HFpEF patients. Given the higher prevalence of heart failure (HF) in the elderly population, testing the screening strategy is imperative to customize it to the specific needs of vulnerable patients who may be more inclined to decline participation in the screening program.
CONDITIONS
Official Title
Copenhagen Heart Failure With Preserved Ejection Fraction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Residence in the Capital Region of Denmark
- Age 50 years or older
- At least two risk factors for HFpEF (or one risk factor if age 60 or older) including hypertension, diabetes mellitus, chronic kidney disease, atrial fibrillation, BMI over 25 kg/m2, previous heart valve surgery, ischemic heart disease, obstructive sleep apnea, or use of 40 mg furosemide
You will not qualify if you...
- Age 90 years or older
- Existing heart failure diagnosis
- Dementia
- Living in a nursing home
- Amyloidosis
- Undergoing hemodialysis
- Cancer diagnosed within the past 5 years (excluding skin cancer)
- Prior solid organ transplant
- Lung diseases including WHO Group 1 pulmonary hypertension, chronic pulmonary embolism, lung fibrosis, chronic obstructive pulmonary disease, or use of home oxygen
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital
Hellerup, Denmark, 2900
Actively Recruiting
Research Team
C
Camilla I Ottosen, MD
CONTACT
T
Tor Biering-Sørensen, MD, MPH, MSc, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here